Published in J Pathol on August 01, 2002
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76
Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol (2002) 2.08
Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. Br J Cancer (2004) 1.77
MUC1 and MUC2 in pancreatic neoplasia. J Clin Pathol (2004) 1.55
Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol (2004) 1.40
Preferential expression of MUC6 in oncocytic and pancreatobiliary types of intraductal papillary neoplasms highlights a pyloropancreatic pathway, distinct from the intestinal pathway, in pancreatic carcinogenesis. Am J Surg Pathol (2010) 1.19
Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol (2013) 1.17
Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol (2010) 1.13
The MUC gene family: their role in diagnosis and early detection of pancreatic cancer. Mol Cancer (2003) 1.06
Non-invasive intraductal papillary neoplasms of the common bile duct: a clinicopathologic study of six cases. Int J Clin Exp Pathol (2012) 1.01
Precursor lesions of pancreatic cancer. Gut Liver (2008) 1.01
Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. J Am Coll Surg (2014) 0.88
Differential expression of MUC genes in endometrial and cervical tissues and tumors. BMC Cancer (2005) 0.86
Hyperplastic polyps and sessile serrated 'adenomas' of the colon and rectum display gastric pyloric differentiation. Histochem Cell Biol (2007) 0.86
Genetic markers of malignant transformation in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Pancreas (2012) 0.86
Intraductal papillary mucinous neoplasm (IPMN) of the gastric-type with focal nodular growth of the arborizing papillae: a case of high-grade transformation of the gastric-type IPMN. Virchows Arch (2006) 0.83
Intraductal papillary-mucinous neoplasia of the pancreas: Histopathology and molecular biology. World J Gastrointest Surg (2010) 0.81
Predictive factors associated with malignancy of intraductal papillary mucinous pancreatic neoplasms. World J Gastroenterol (2010) 0.81
The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes. Mod Pathol (2016) 0.79
Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. Virchows Arch (2016) 0.76
The molecular background of mucinous carcinoma beyond MUC2. J Pathol Clin Res (2014) 0.76
Intraductal Tubulopapillary Neoplasm of the Pancreas: A Clinicopathologic and Immunohistochemical Analysis of 33 Cases. Am J Surg Pathol (2016) 0.75
The outcome of ipsilateral hemihepatectomy in mucin-producing bile duct tumors. PLoS One (2014) 0.75
Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas. World J Gastroenterol (2014) 0.75
Human pancreatic cancer fusion 2 (HPC2) 1-B3: a novel monoclonal antibody to screen for pancreatic ductal dysplasia. Cancer Cytopathol (2012) 0.75
Exploring the role and diversity of mucins in health and disease with special insight into non-communicable diseases. Glycoconj J (2015) 0.75
Multicentric invasive carcinomas derived from intraductal papillary mucinous neoplasm (IPMN) of the pancreas: report of a case. Virchows Arch (2007) 0.75
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.93
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 7.65
Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med (2014) 6.10
Arthritis critically dependent on innate immune system players. Immunity (2002) 5.31
Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol (2007) 3.86
The "50-50 criteria" on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg (2005) 3.46
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol (2009) 3.18
Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg (2003) 3.16
Amanita phalloides poisoning: reassessment of prognostic factors and indications for emergency liver transplantation. J Hepatol (2006) 3.14
ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology (2012) 3.00
Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med (2002) 2.98
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology (2007) 2.95
External pancreatic duct stent decreases pancreatic fistula rate after pancreaticoduodenectomy: prospective multicenter randomized trial. Ann Surg (2011) 2.60
Hereditary pancreatitis caused by triplication of the trypsinogen locus. Nat Genet (2006) 2.44
Hemorrhage after pancreaticoduodenectomy: when is surgery still indicated? Am J Surg (2007) 2.44
Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas. Am J Gastroenterol (2006) 2.34
Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol (2002) 2.30
Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases. J Am Coll Surg (2003) 2.20
Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol (2002) 2.08
Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg (2003) 2.03
Arthritogenic monoclonal antibodies from K/BxN mice. J Exp Med (2002) 1.94
Paraganglioma after maternal transmission of a succinate dehydrogenase gene mutation. J Clin Endocrinol Metab (2008) 1.94
Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med (2010) 1.92
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology (2009) 1.92
Ischemic complications after pancreaticoduodenectomy: incidence, prevention, and management. Ann Surg (2009) 1.89
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology (2012) 1.86
Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma. Surgery (2002) 1.76
Major hepatectomy for the treatment of complex bile duct injury. Ann Surg (2008) 1.74
Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy. Clin Gastroenterol Hepatol (2006) 1.74
Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol (2006) 1.71
Pancreas divisum is not a cause of pancreatitis by itself but acts as a partner of genetic mutations. Am J Gastroenterol (2011) 1.71
A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology (2009) 1.70
ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology (2012) 1.68
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology (2012) 1.67
Reappraisal of central pancreatectomy a 12-year single-center experience. JAMA Surg (2014) 1.62
Impaired E-cadherin expression and glutamine synthetase overexpression in solid pseudopapillary neoplasm of the pancreas. Pancreas (2008) 1.60
Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab (2013) 1.59
Retention of Plasmodium falciparum ring-infected erythrocytes in the slow, open microcirculation of the human spleen. Blood (2008) 1.58
Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans. J Histochem Cytochem (2004) 1.58
Is idiopathic chronic pancreatitis an autoimmune disease? Clin Gastroenterol Hepatol (2005) 1.57
Histologic scoring of liver biopsy in focal nodular hyperplasia with atypical presentation. Hepatology (2002) 1.55
Incidence and consequence of an hepatic artery injury in patients with postcholecystectomy bile duct strictures. Ann Surg (2003) 1.54
Staging of pancreatic head adenocarcinoma with spiral CT and endoscopic ultrasonography: an indirect evaluation of the usefulness of laparoscopy. Pancreatology (2004) 1.54
Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology (2005) 1.54
The sensing of poorly deformable red blood cells by the human spleen can be mimicked in vitro. Blood (2010) 1.52
Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology (2008) 1.51
Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol (2006) 1.49
Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1. J Biol Chem (2002) 1.49
Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg (2010) 1.48
Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology (2005) 1.48
The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood (2008) 1.48
Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the Association Française de Chirurgie. Ann Surg Oncol (2015) 1.46
Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer (2011) 1.46
Two hundred liver hanging maneuvers for major hepatectomy: a single-center experience. Ann Surg (2007) 1.44
Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology (2003) 1.42
MSH2 in contrast to MLH1 and MSH6 is frequently inactivated by exonic and promoter rearrangements in hereditary nonpolyposis colorectal cancer. Cancer Res (2002) 1.41
Clinical and autopsy diagnoses in the intensive care unit: a prospective study. Arch Intern Med (2004) 1.41
Ex vivo perfusion of human spleens maintains clearing and processing functions. Blood (2005) 1.39
Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology (2002) 1.35
Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology (2006) 1.34
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). J Thorac Oncol (2012) 1.32
Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas (2008) 1.31
Pancreatic fistula after distal pancreatectomy: predictive risk factors and value of conservative treatment. Arch Surg (2006) 1.30
Conservative management of pancreatic fistula after pancreaticoduodenectomy with pancreaticogastrostomy. J Am Coll Surg (2004) 1.29
Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study. Clin Gastroenterol Hepatol (2008) 1.29
Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: a study in 17 explanted livers. Hepatology (2003) 1.28
Leiden Open Variation Database of the MUTYH gene. Hum Mutat (2010) 1.28
Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells. Cancer Res (2010) 1.27
Fatty pancreas and increased body mass index are risk factors of pancreatic fistula after pancreaticoduodenectomy. Surgery (2010) 1.26
Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology (2004) 1.26
Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl (2004) 1.26
Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol (2006) 1.26
Activation of NF-kappa B, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J Hepatol (2002) 1.25
Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol (2008) 1.22
Evaluation of Lynch syndrome modifier genes in 748 MMR mutation carriers. Eur J Hum Genet (2011) 1.21
Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors. Clin Cancer Res (2008) 1.19